After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
One critical aspect is the recent approval of KarXT for schizophrenia, which, although positive, was anticipated and thus unlikely to significantly affect the stock’s value. The drug’s labeling was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback